Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double‐blind parallel‐group trial

Huttunen, Matti; Piepponen, T.P.; Rantanen, Helena; Larmo, Ilkka; Nyholm, R.; Raitasuo, Virpi

doi:10.1111/j.1600-0447.1995.tb09781.x

Cited by 92 publications

(44 citation statements)

References 23 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It also possesses some short-acting norepinephrine receptor antagonist activity, as well as some antihistaminergic activity (Leysen et al 1988;Janssen et al 1988). Studies have shown that it is at least as effective as the typical neuroleptics in patients with acute and chronic schizophrenia with positive and/or negative symptoms (Chouinard et al 1993;Hoyberg et al 1993;Marder and Meibach 1994;Carman et al 1995;Huttunen et al 1995;Peuskens and the Risperidone Study Group 1995) and that it is better tolerated than typical neuroleptics in terms of extrapyramidal side effects (Geddes et al 2000).…”

mentioning

confidence: 99%

Amisulpride vs. Risperidone in Chronic Schizophrenia Results of a 6-month Double-blind Study

Sechter

Fleurot

Rein

et al. 2002

Neuropsychopharmacology

106

View full text Add to dashboard Cite

Schizophrenia is a chronic and disabling disorder with a lifetime prevalence of approximately 1% (American Psychiatric Association 1994). It results in significant long-term functional handicap, severely impairs the quality of life of both the patient and the caregivers and places a considerable financial burden on society.The clinical efficacy of amisulpride against acute psychotic symptoms at high doses (400-800 mg/day) and prominent negative symptoms at low doses (50-300 mg/day) may be explained by its preferential affinity for pre-synaptic dopaminergic D 2 and D 3 autoreceptor subtypes at low doses, while higher doses result in predominant antagonism of post-synaptic dopamine receptors (Perrault et al. 1997;Schoemaker et al. 1997). It also shows selectivity for dopamine receptors in limbic and hippocampal structures, rather than striatal structures, thus suggesting a lower propensity to induce extrapyramidal effects than seen with the classical antipsychotics (Perrault et al. 1997). Studies in

show abstract

mentioning

confidence: 99%

Amisulpride vs. Risperidone in Chronic Schizophrenia Results of a 6-month Double-blind Study

Sechter

Fleurot

Rein

et al. 2002

Neuropsychopharmacology

106

View full text Add to dashboard Cite

show abstract

“…However, the differences between the 2 drugs in schizophrenia subjects have been pointed out elsewhere (6,13). In samples with and without dual diagnosis, risperidone and zuclopenthixol were equally effective in reducing positive, but not negative, symptomatology.…”

Section: Discussionmentioning

confidence: 99%

“…Zuclopenthixol is a well-established thioxanthene antipsychotic. Zuclopenthixol's controlled studies have shown that this antipsychotic is as effective as chlorpromazine (12) and risperidone (13) in the treatment of schizophrenia patients. It can be administered intramuscularly or orally.…”

mentioning

confidence: 99%

Long-Acting Injectable Risperidone Compared with Zuclopenthixol in the Treatment of Schizophrenia with Substance Abuse Comorbidity

et al. 2006

View full text Add to dashboard Cite

Objective: This study aimed to compare the efficacy of long-acting risperidone and zuclopenthixol in subjects with schizophrenia and substance abuse. Method:A total of 115 subjects with schizophrenia and substance use disorders were enrolled for an open, randomized, controlled, 6-month follow-up study. Fifty-seven subjects were selected for treatment with long-acting injectable risperidone, while another 58 were treated with zuclopenthixol-depot.Results: Long-acting risperidone patients presented fewer positive urine tests (8.67 compared with 10.36, P = 0.005), showed improved scores on the Positive and Negative Syndrome Scale, and showed better compliance with the Substance Abuse Management program. The use of long-acting risperidone and less severe dependence explained the outcome at the end of the follow-up.Conclusions: Long-acting injectable risperidone was more effective than zuclopenthixol-depot in improving substance abuse and schizophrenia symptoms in subjects with dual diagnosis. (Can J Psychiatry 2006;51:531-539) Information on funding and support and author affiliations appears at the end of the article. Clinical Implications· Long-acting risperidone is more effective than zuclopenthixol-depot in improving substance abuse in subjects with schizophrenia. · Long-acting risperidone improves the efficacy of a cognitive-behavioural program for managing substance abuse. · Atypical antipsychotics could be the best pharmacologic strategy in the treatment of subjects with schizophrenia and substance abuse comorbidity. Limitations· The study had an open design. · Results may not be generalizable to other clinical populations. · We included subjects with family support.

show abstract

“…In the original review, 23 studies were identified for inclusion: Blin 1996, 251 Borison 1991, 252 Bouchard 1998, 253 Ceskova 1993, 254 Chouinard 1993, 255 Claus 1991, 256 Emsley 1995, 257 Hoyberg 1993, 258 Huttunen 1995, 259 Mahmoud 1998, 260 Marder 1994, 116 Mesotten 1991, 261 Min 1993, 262 Peuskens 1995, 263 Fleurot 1997, 62 Bondolfi 1998, 110 Anand 1998, 111 Breier 1999, 112 Wahlbeck 2000, 113 Tran 1997, 171 Klieser 1996, 264 Jones 1998, 193 Gureje 1998. 186 Data extraction sheets for these studies are presented in appendix 3.…”

Section: Old Rctsmentioning

confidence: 99%

A systematic review of atypical antipsychotic drugs in schizophrenia

Bagnall

Jones

Ginnelly

et al. 2003

Health Technol Assess

151

114

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. Contact Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAA systematic review of atypical antipsychotic drugs in schizophrenia NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.The research reported in this monograph was commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence (NICE). Technology assessment reports are completed in a limited time to inform the appraisal and guidance development processes managed by NICE. The review brings together evidence on key aspects of the use of the technology concerned. However, appraisals and guidance produced by NICE are informed by a wide range of sources.The research reported in this monograph was funded as project number 00/20/01.The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors. Criteria for inclusion in the HTA monograph seriesReports are published in the HTA monograph series if (1) they have resulted from work commissioned for the HTA Programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.Reviews in Health Technology Assessment are termed 'syst...

show abstract

Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double‐blind parallel‐group trial

Cited by 92 publications

References 23 publications

Amisulpride vs. Risperidone in Chronic Schizophrenia Results of a 6-month Double-blind Study

Amisulpride vs. Risperidone in Chronic Schizophrenia Results of a 6-month Double-blind Study

Long-Acting Injectable Risperidone Compared with Zuclopenthixol in the Treatment of Schizophrenia with Substance Abuse Comorbidity

A systematic review of atypical antipsychotic drugs in schizophrenia

Contact Info

Product

Resources

About